Triple-strength Wegovy pen approved

The Medicines and Healthcare products Regulatory Agency gave the green light to the new pen, marking a major shift in how obesity is treated within the NHS. Clinical trials suggest the higher dosage can nearly double the rate of weight loss for some patients.

However, experts have cautioned about potential side effects, with a new study highlighting that 43% of users report issues like fatigue and menstrual changes.

The approval comes as demand for GLP-1 medications continues to surge globally, putting pressure on supply chains and healthcare budgets.